Fluicell

Fluicell CapEx/OCF

The CapEx to Operating Cash Flow Ratio of Fluicell (FLUI.ST) as of Nov 20, 2026 is -100.00 %. In the previous year, CapEx to Operating Cash Flow Ratio was -22.27 % — a change of 348.97% (lower).

CapEx/OCF

-100.00 %

YoY

348.97%

Last updated:

CapEx to Operating Cash Flow Ratio of Fluicell is 2025 -100.00 % . CapEx to Operating Cash Flow Ratio of Fluicell was 2024 -22.27 % . It decreases by 348.97% lower compared to the previous year.

The Fluicell CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
-12.49 SEK
Jan 1, 2019
-4.76 SEK
Jan 1, 2020
-1.88 SEK
Jan 1, 2021
-4.14 SEK
Jan 1, 2022
-5.40 SEK
Jan 1, 2023
0.00 SEK
Jan 1, 2024
-22.27 SEK
Jan 1, 2025
-100.00 SEK
The Fluicell CapEx/OCF history
YEARCapEx/OCFYoY
-100.00 %+348.97%
-22.27 %—
0.00-100.00%
-5.40 %+30.35%
-4.14 %+119.83%
-1.88 %-60.40%
-4.76 %-61.92%
-12.49 %+95.68%
-6.38 %+322.86%
-1.51 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fluicell Stock analysis

What does Fluicell do? Fluicell AB commercializes research tools BioPen and Dynaflow Resolve for studying, processing, and measuring drug impact on individual cells in cell-based pharmacology research. The company also develops bioprinting technology Biopixlar Retina, offering 2D and 3D options to create complex tissue-like structures with precise cell positioning control. These products target drug development research segments where individual cell analysis is critical. The primary buyers are pharmaceutical companies and research institutions focused on cell-based pharmacology. Fluicell AB's product portfolio includes BioPen, Dynaflow Resolve, and Biopixlar Retina, all designed for cell-based pharmacology research applications. The company's tools enable detailed analysis of drug effects at the single-cell level, supporting pharmaceutical research and development processes. Biopixlar Retina specifically addresses tissue engineering needs by allowing controlled creation of tissue-like structures in both 2D and 3D formats. The company's revenue streams come from selling these research tools and bioprinting technologies to pharmaceutical companies and research institutions. These segments value the precision and control offered by Fluicell's products for cell-based drug development studies. The products are positioned as essential tools for advanced cell analysis in pharmacology research environments. Fluicell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fluicell stock

CapEx to Operating Cash Flow Ratio of Fluicell is -100.00 % in 2025.

CapEx to Operating Cash Flow Ratio of Fluicell changed from -22.27 % to -100.00 %, representing a 348.97% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Fluicell since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Fluicell with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Fluicell

All Key Metrics — Fluicell